{
  "20-Aug-2025": [
    {
      "doctor": "Chong Qingging Dawn",
      "section_type": "Pre-clerk Consult",
      "text": {
        "General": "DMO Pre-clerk Consult Note NCC [Charted Location: Pre-Admit] [Authored: 2025-08-20 00:13]- for Visit: H225121881F0002, Incomplete, Entered, Signed in Full, General CLINICAL NOTES:",
        "History, Examination and Investigations": "seen as blue letter Ward 58/26/5 61 Chinese Male NKDA $: No private insurance (unable to buy Rider as DM >10 years) P/S Hx: Married lives with wife 1 adopted daughter Wife s/p TAHBSO for endometrial cancer Works as sales and marketing manager Non-smoker and non-drinker Family Hx: Mother - diagnosed with breast cancer 60+ years old Father - prostate and bladder cancer 60+ years old Sister - breast cancer 60+ years old 2nd sister - endometrial cancer 60+ years old No previous counselling for genetic screening PMHx: 1.HTN HLD 2.DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Admitted since 2/8/25 for SOBOE x4-5/12 - gradually worsening - a/w Reduced effort tolerance - walking slower than usual, more effort to climb up overhead bridge - a/w occasional vertiginous giddiness x3/7 - worse with movement and changes in head position - LOW 8kg over 1 year (since May 2024) with intermittent LOA - no progesterone receptor bleed/change in stool caliber POD 4 S> No fever SBP 120-160s Saturating 98-100% on RA Denies any pain so far Able to pass flatus 2025-09-26 14:27  Current Location: NCC ATU L10 Taking 300mls FF + 1/2 share porridge 1-300 0-200 Blake drain-200mls BNO x 1/7 On examination:: No LN palpable L clear Abd soft NT, post-op wound dry and clean, blake drain in situ Ext no edema ISSUES: 1.Newly diagnosed metastatic ascending colon Ca - SOD: significant burden in the liver, bilateral lung with largest at 7.8cm R lower lobe, LNs - presented with symptomatic anaemia, LOW - MRCP (1/8/25) done in private: >Liver enlarged secondary to multiple heterogenously enhancing liver masses suspicious for metastatic lesions >Circumferential mass involving the ascending colon, suspicious for a primary colonic malignancy. >Extensive paracolic fat stranding and nodularity suspicious for extra-serosal extension of disease. >Diffuse mesenteric and omental fat stranding is noted with no significant upper abdominal ascites >Multiple enlarged paracolic, mesenteric, upper abdominal (including super mesenteric and common hepatic artery nodes) and upper retroperitoneal lymphadenopathy. >Suspicious subcentimeter right inferior internal mammary lymph node >Heterogenous lung mass at the right infrahilar region, likely within the medial basal aspect of the right lower lobe as well as a partially imaged left perihilar lung lesion, suspicious for metastases >Cholelithiasis noted. No dilatation of the common bile duct - No clinical suggestion of obstruction or active bleed - Colonoscopy 5/8/25 : >Scoped to ascending colon. >Circumferential stenosing mass with pinpoint lumen. Unable to scope past. >No evidence of bleeding. Multiple biopsies taken with jumbo forceps - Histo 5/8/25: >Ascending colon tumour; biopsies: Adenocarcinoma, provisionally moderately differentiated >Immunohistochemistry for DNA mismatch repair proteins is pending and will be reported in an addendum. - CT TAP 6/8/25 : >Findings are compatible with primary malignancy of the ascending colon-caecum, possibly involving the terminal ileum with lung, liver and nodal metastases. - S/p Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for Metastatic ascending colon cancer with impending obstruction >Bulky right sided colon tumor extending from ileocecal junction close to hepatic flexure >No peritoneal metastases >Duodenum and right ureter visualized and preserved - histo from op still pending - Blood tests: >10/08/25: HGb-9.3, TW-9.24, PIt-560 2025-09-26 14:27  Current Location: NCC ATU L10 >10/08/25: Na-135, K-4.2, Bicarb-29.1, Crea-56 >07/08/25: Tbil-15, ALP-203, GGT-149, ALT-11, AST-25, albumin-27 >07/08/25: ca-2.23, po4-1.24, mg-0.73 - Done in private: CEA 683, CA 19-9 944 Complicated by: a.Symptomatic anaemia with Haemoglobin drop likely 2 occult GI bleeding from colonic tumour - Anaemia panel done in private 31/7/25: >Iron 1.9 TIBC 57 Iron sat 3% Transferrin 2.7 Ferritin 21 >Haemoglobin electrophoresis: HbA2 1.5 HbF <0.5 HBH inclusion bodies not detected >PBF: moderate degree of thrombocytosis. Dyserythropoietic changes present >Vit B12 565 | Folate 24.8 (31/7/25) - No active bleeding clinically - Haemoglobin 4.7 OA > 2 PCT given > 6.5 > 1 PCT given > 7.5 > 7.7 > 8.1 > 8.5 > 9.3 b.Deranged LFT possibly 2' bilobar liver mets - 31/7/25 (done in private): HBsAg -ve | anti-HBs -ve | anti- HAV -ve | anti-HCV -ve | HIV -ve 2.Nosocomial fever ?source possibly Gl translocation from colonic tumour - DDx: malignant fever - T38C on 5/8/25 with no localising symptoms - C-Reactive Protein 36 - UFEME RBC 144 WBC 5 - urine c/s 5/8/25: mixed bacterial growth - blood c/s 5/8/25 : aerobic NBG after 48hrs , anaerobic NBG after 48hrs 3.Mild LL swelling possibly 2' compressive pelvic lymphadenopathy, ?nephrotic syndrome b/g DM - Albumin 32 - NTproBNP 50.6 - b/g DM HbAt1c 7.1% 31/7/25, UACr June'25 7mg/mmol - uPCr 0.29 COMMS: S/T px and wife - explained results of",
        "Investigations": "suggestive of metastatic colon cancer - SOD mentioned: significant burden in the liver, bilateral lung with largest at 7.8cm R lower lobe, LNs - given extent of disease involvement on initial CT, already considered as stage 4 >given significant disease burden in the liver need to monitor LFT - overall treatment intent remains palliative still and unable to gurantee cure - aim is to preserve QOL, help in symptoms and hopefully prolong life expectancy - discussed treatment options generally may include: 1.systemic therapy a.chemo (ex. 5FU based combination such as XELOX) +/- biologics - noted will send off further test (MMR, SSTP and Her2) to determine further systemic treatment options KIV add on subsequent cycles - briefly mentioned re: XELOX and its schedule and patient handout given - mentioned chemo SE: - myelosuppression with risk for infections, fatigue, constipation, diarrhea, nausea, vomiting, mucositis, neuropathy, anaphylactic reactions, organ dysfunction and other treatment-related mortalities (<1%) and all relevant treatment-related toxicities. - decision for chemo will overall depend on subsequent review such as organ function and overall fitness 2025-09-26 14:27  Current Location: NCC ATU L10 - chemo is modifiable as well depending on tolerability and response - interval scan done after 2-3 months to assess response b.immunotherapy - depending on MMR status 2.BSC- if px not keen - for now we prioritise to start systemic treatment after at least 2 weeks from post op to facilitate wound healing and recovery - family mentioned as per discussion with other relatives they maybe seeking second opinion and requested for blood tests and scan results - understands and all questions answered Plan: SUGGEST: Trace intraop histo as well - Please send colonoscopy specimen histo for MMR IHC, Her2 and colon SSTP Pls repeat cea, ca19-9 on next blood test POst op care as per primary team Team to pls provide copy of the scan and blood test report for second opinion Cont to trend and monitor LFT for now If planned for home TCU DMO GI Con as new case with memo, fbc, ue, Ift, cea, ca19-9 OA in 2/52 time Refer genetics as outpx Please keep us updated on px progress ADDENDUM on 12/8/25: Discussed with Dr Dawn Chong Do hepBsAg, CEA next blood taking TCU 20/8/25 930 am special arrangement Full Blood Count UECR LFT OA Chemo wise, can discuss XELOX/FOLFOX - if very fit, can even consider FOLFOXIRI came with wife S: Ole: L clear A soft non tender wound healed? Inv labs CEA 538 hep b neg (A) Limited right hemicolectomy specimen: Two moderately differentiated adenocarcinomas of colon; - pT3(m) N2b Mx. 2025-09-26 14:27  Current Location: NCC ATU L10 - tumour deposits seen in mesenteric margin and omentum. - proximal and distal margins clear. - normal expression of DNA mismatch repair proteins.  c-erb-B2 negative. SSTP pending Imp: fit for chemotherapy ? explained mets colon cancer to lung, liver, lymph node chemotherapy for control not cure options XELOX FOLFOxX - need porta cath Side effects include: nausea/vomiting, hair loss, low red blood cell count or anemia, fatigue, poor appetite, dysgeusia, risk of infection, risk of bleeding, diarrhea, sores of mouth and throat, skin and nail effects, palmar-plantar erythrodysesthesia, hyperpigmentation, numbness, cold dysesthesia, nerve effects, arrhythmias, heart attacks/heart effects, liver effects, kidney effects, sexual effects, reproductive/fertility effects, allergic/nypersensitivity reactions etc. Side effects particular to each drug include Oxaliplatin: Numbness and tingling in the fingers and/or feet, more likely with longer durations of therapy. Oxaliplatin can also cause an unusual sensitivity to cold temperatures. This can result in painful spasms of the throat while inhaling cold air or ingesting cold liquids. Fatigue, laryngeal spasms, allergic reactions and taste changes can also occur. Xeloda: Tenderness and soreness of palms of the hands and the soles of the feet, change in nail beds, increased sensitivity to sun, and darkening and hardening of the vein used for giving 5FU can occur. Diarrhea, mouth sores, fatigue, weakness, muscle aches, and headaches, chest pain, angina can also occur. 5FU: Tenderness and soreness of palms of the hands and the soles of the feet, change in nail beds, increased sensitivity to sun, and darkening and hardening of the vein used for giving 5FU can occur. Diarrhea, mouth sores, fatigue, weakness, muscle aches, and headaches, chest pain, angina can also occur. Patient was informed that in the event of severe complications from chemotherapy, this could be life threatening and cause death. Patient was informed that other side effects which are not listed above or not reported by others could occur. Each patient can respond differently to chemotherapy and could have side effects that have not been reported by others. Patient was informed that he/she could stop the treatment at any time. Patient's questions about this treatment were answered. Patient understood the rationale and potential side effects and agreed to proceed with chemotherapy. consent to Xelox taken",
        "Clinical and Treatment Summary": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction 2025-09-26 14:27  Current Location: NCC ATU L10 PMHx: 1. HTN 2. HLD 3. DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Treatment Intent: Palliative therapy Patient Response: NE ECOG: 1 Pain Score:: 0",
        "PATIENT STATUS": "Allergy Information: No Known Allergies. Adverse Reactions (Nursing Notes): No Hypersensitivity reaction available.",
        "MANAGEMENT FOR THIS VISIT": "KIV XELOX TCU 3 weeks with Full Blood Count,UE, LFT, CEA OA prebk #2 XELOX return advise given ATU: proceed if Haemoglobin > 8 Absolute Neutrophil Count > 1.5 platelet > 100 CCT > 50 Bil < 1.5x ULN, AST/ALT < 2x ULN"
      },
      "subsections": [
        "General",
        "History, Examination and Investigations",
        "Investigations",
        "Clinical and Treatment Summary",
        "PATIENT STATUS",
        "MANAGEMENT FOR THIS VISIT"
      ],
      "allergies": "NKA"
    },
    {
      "doctor": "Chong Qingqging Dawn",
      "section_type": "Consult",
      "text": {
        "General": "Pe DMO Consult Note NCC [Charted Location: NCC Clinic 14E] [Authored: 2025-08-20 09:39]- for Visit: H225121881F0002, Complete, Revised, Signed in Full, General Height & Weight: Weight (kg): 64.4 kg 2025-08-20 09:37:52. Height (cm): 171.5 cm 2025-08-20 09:37:52. CLINICAL NOTES: Visit/Appointment Date: 2025-08-20 2025-09-26 14:27  Current Location: NCC ATU L10",
        "History, Examination and Investigations": "seen as blue letter 61 Chinese Male NKDA $: No private insurance (unable to buy Rider as DM >10 years) P/S Hx: Married lives with wife 1 adopted daughter Wife s/p TAHBSO for endometrial cancer Works as sales and marketing manager social smoker and non-drinker Family Hx: Mother - diagnosed with breast cancer 60+ years old Father - prostate and bladder cancer 60+ years old Sister - breast cancer 60+ years old 2nd sister - endometrial cancer 60+ years old No previous counselling for genetic screening PMHx: 1.HTN HLD 2.DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Admitted since 2/8/25 for SOBOE x4-5/12 - gradually worsening - alw Reduced effort tolerance - walking slower than usual, more effort to climb up overhead bridge - a/w occasional vertiginous giddiness x3/7 - worse with movement and changes in head position - LOW 8kg over 1 year (since May 2024) with intermittent LOA - no progesterone receptor bleed/change in stool caliber POD 4 S> No fever SBP 120-160s Saturating 98-100% on RA Denies any pain so far Able to pass flatus Taking 300mls FF + 1/2 share porridge 1-300 O-200 Blake drain-200mls BNO x 1/7 On examination:: No LN palpable L clear Abd soft NT, post-op wound dry and clean, blake drain in situ 2025-09-26 14:27  Current Location: NCC ATU L10 Ext no edema ISSUES: 1.Newly diagnosed metastatic ascending colon Ca - SOD: significant burden in the liver, bilateral lung with largest at 7.8cm R lower lobe, LNs - presented with symptomatic anaemia, LOW, dyspnoea - MRCP (1/8/25) done in private: >Liver enlarged secondary to multiple heterogenously enhancing liver masses suspicious for metastatic lesions >Circumferential mass involving the ascending colon, suspicious for a primary colonic malignancy. >Extensive paracolic fat stranding and nodularity suspicious for extra-serosal extension of disease. >Diffuse mesenteric and omental fat stranding is noted with no significant upper abdominal ascites >Multiple enlarged paracolic, mesenteric, upper abdominal (including super mesenteric and common hepatic artery nodes) and upper retroperitoneal lymphadenopathy. >Suspicious subcentimeter right inferior internal mammary lymph node >Heterogenous lung mass at the right infrahilar region, likely within the medial basal aspect of the right lower lobe as well as a partially imaged left perihilar lung lesion, suspicious for metastases >Cholelithiasis noted. No dilatation of the common bile duct - No clinical suggestion of obstruction or active bleed - Colonoscopy 5/8/25 : >Scoped to ascending colon. >Circumferential stenosing mass with pinpoint lumen. Unable to scope past. >No evidence of bleeding. Multiple biopsies taken with jumbo forceps - Histo 5/8/25: >Ascending colon tumour; biopsies: Adenocarcinoma, provisionally moderately differentiated >Immunohistochemistry for DNA mismatch repair proteins is pending and will be reported in an addendum. - CT TAP 6/8/25 : >Findings are compatible with primary malignancy of the ascending colon-caecum, possibly involving the terminal ileum with lung, liver and nodal metastases. - S/p Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for Metastatic ascending colon cancer with impending obstruction >Bulky right sided colon tumor extending from ileocecal junction close to hepatic flexure >No peritoneal metastases >Duodenum and right ureter visualized and preserved - histo from op still pending - Blood tests: >10/08/25: HGb-9.3, TW-9.24, PIt-560 >10/08/25: Na-135, K-4.2, Bicarb-29.1, Crea-56 >07/08/25: Tbil-15, ALP-203, GGT-149, ALT-11, AST-25, albumin-27 >07/08/25: ca-2.23, po4-1.24, mg-0.73 - Done in private: CEA 683, CA 19-9 944 Complicated by: a.Symptomatic anaemia with Haemoglobin drop likely 2' occult GI bleeding from colonic tumour - Anaemia panel done in private 31/7/25: >lron 1.9 TIBC 57 Iron sat 3% Transferrin 2.7 Ferritin 21 >Haemoglobin electrophoresis: HbA2 1.5 HbF <0.5 HBH inclusion bodies not detected >PBF: moderate degree of thrombocytosis. Dyserythropoietic changes present 2025-09-26 14:27  Current Location: NCC ATU L10 >Vit B12 565 | Folate 24.8 (31/7/25) - No active bleeding clinically - Haemoglobin 4.7 OA > 2 PCT given > 6.5 > 1 PCT given > 7.5 > 7.7 > 8.1 >8.5> 9.3 b.Deranged LFT possibly 2' bilobar liver mets - 31/7/25 (done in private): HBsAg -ve | anti-HBs -ve | anti-HAV -ve | anti-HCV -ve | HIV -ve 2.Nosocomial fever ?source possibly Gl translocation from colonic tumour - DDx: malignant fever - T38C on 5/8/25 with no localising symptoms - C-Reactive Protein 36 - UFEME RBC 144 WBC 5 - urine c/s 5/8/25: mixed bacterial growth - blood c/s 5/8/25 : aerobic NBG after 48hrs , anaerobic NBG after 48hrs 3.Mild LL swelling possibly 2' compressive pelvic lymphadenopathy, ?nephrotic syndrome b/g DM - Albumin 32 - NTproBNP 50.6 - b/g DM HbAtc 7.1% 31/7/25, UACr June'25 7mg/mmol - uPCr 0.29 COMMS: S/T px and wife - explained results of",
        "Investigations": "suggestive of metastatic colon cancer - SOD mentioned: significant burden in the liver, bilateral lung with largest at 7.8cm R lower lobe, LNs - given extent of disease involvement on initial CT, already considered as stage 4 >given significant disease burden in the liver need to monitor LFT - overall treatment intent remains palliative still and unable to gurantee cure - aim is to preserve QOL, help in symptoms and hopefully prolong life expectancy - discussed treatment options generally may include: 1.systemic therapy a.chemo (ex. 5FU based combination such as XELOX) +/- biologics - noted will send off further test (MMR, SSTP and Her2) to determine further systemic treatment options KIV add on subsequent cycles - briefly mentioned re: XELOX and its schedule and patient handout given - mentioned chemo SE: - myelosuppression with risk for infections, fatigue, constipation, diarrhea, nausea, vomiting, mucositis, neuropathy, anaphylactic reactions, organ dysfunction and other treatment-related mortalities (<1%) and all relevant treatment-related toxicities. - decision for chemo will overall depend on subsequent review such as organ function and overall fitness - chemo is modifiable as well depending on tolerability and response - interval scan done after 2-3 months to assess response b.immunotherapy - depending on MMR status 2.BSC- if px not keen - for now we prioritise to start systemic treatment after at least 2 weeks from post op to facilitate wound healing and recovery - family mentioned as per discussion with other relatives they maybe seeking second opinion and requested for blood tests and scan results - understands and all questions answered 2025-09-26 14:27  Current Location: NCC ATU L10 Plan: SUGGEST: Trace intraop histo as well - Please send colonoscopy specimen histo for MMR IHC, Her2 and colon SSTP Pls repeat cea, ca19-9 on next blood test POst op care as per primary team Team to pls provide copy of the scan and blood test report for second opinion Cont to trend and monitor LFT for now If planned for home TCU DMO GI Con as new case with memo, fbc, ue, Ift, cea, ca19-9 OA in 2/52 time Refer genetics as outpx Please keep us updated on px progress ADDENDUM on 12/8/25: Discussed with Dr Dawn Chong Do hepBsAg, CEA next blood taking TCU 20/8/25 930 am special arrangement Full Blood Count UECR LFT OA Chemo wise, can discuss XELOX/FOLFOX - if very fit, can even consider FOLFOXIRI 1 week + post op came with wife, daughter and sister in law S: intermittent abd pain when you walk much BO every 2 days no progesterone receptor bleed appetite ok seeing Ben Chua cm Ole: L clear A soft non tender wound healed steristrip over drain side - clean no pedal edema Inv Full Blood Count, Cr ok AST 56 CEA 538 Hep b neg (A) Limited right hemicolectomy specimen: Two moderately differentiated adenocarcinomas of colon; - pT3(m) N2b Mx. - tumour deposits seen in mesenteric margin and omentum. 2025-09-26 14:27  Current Location: NCC ATU L10 - proximal and distal margins clear. - normal expression of DNA mismatch repair proteins. - c-erb-B2 negative. SSTP pending Imp: fit for chemotherapy explained mets colon cancer to lung, liver, lymph node CT images shown chemotherapy for control not cure Options 1. XELOX 2. FOLFOX 3. FOLFOXIRI - need porta cath for 5FU response rate higher with 3 agents Kiv add on targeted therapy dep on SSTP not eligible for immunotherapy Side effects include: nausea/vomiting, hair loss, low red blood cell count or anemia, fatigue, poor appetite, dysgeusia, risk of infection, risk of bleeding, diarrhea, sores of mouth and throat, skin and nail effects, palmar-plantar erythrodysesthesia, hyperpigmentation, numbness, cold dysesthesia, nerve effects, arrhythmias, heart attacks/heart effects, liver effects, kidney effects, sexual effects, reproductive/fertility effects, allergic/nypersensitivity reactions etc. Side effects particular to each drug include Oxaliplatin: Numbness and tingling in the fingers and/or feet, more likely with longer durations of therapy. Oxaliplatin can also cause an unusual sensitivity to cold temperatures. This can result in painful spasms of the throat while inhaling cold air or ingesting cold liquids. Fatigue, laryngeal spasms, allergic reactions and taste changes can also occur. Xeloda: Tenderness and soreness of palms of the hands and the soles of the feet, change in nail beds, increased sensitivity to sun, and darkening and hardening of the vein used for giving 5FU can occur. Diarrhea, mouth sores, fatigue, weakness, muscle aches, and headaches, chest pain, angina can also occur. SFU: Tenderness and soreness of palms of the hands and the soles of the feet, change in nail beds, increased sensitivity to sun, and darkening and hardening of the vein used for giving 5FU can occur. Diarrhea, mouth sores, fatigue, weakness, muscle aches, and headaches, chest pain, angina can also occur. Patient was informed that in the event of severe complications from chemotherapy, this could be life threatening and cause death. Patient was informed that other side effects which are not listed above or not reported by others could occur. Each patient can respond differently to chemotherapy and could have side effects that have not been reported by others. Patient was informed that he/she could stop the treatment at any time. Patients questions about this treatment were answered. Duration of chemotherapy - long term patient wants some time to think abt chemotherapy options but agreeable to porta cath informed may need adm for chemotherapy if porta cath date far 2025-09-26 14:27  Current Location: NCC ATU L10 Vital Signs: BP 137 / 75mmbHg (12 Aug 2025 16:35:00:000) Ht: 171.5 cm (2025-08-20 09:37:52) Wt: 64.4 kg (2025-08-20 09:37:52) BSA: 1.75 m2 BMI: 21.9 Future Appointments: 27/08/2025 16:00:00 SGH DIETETICS DIT CDLD, BLK 3 B1 (Yellow Zone) 27/08/2025 14:00:00 NCC SURGERY & SURGICAL ONCOLOGY SON CLINIC 14F -NCCS (Outram) Level 14 Cai Mingzhe 22/08/2025 14:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10",
        "Clinical and Treatment Summary": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction PMHx: 1. HTN 2. HLD 3. DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Treatment Intent: Palliative therapy Patient Response: NE ECOG: 1 Pain Score:: 0 Allergy Acknowledgement: | have acknowledged the patient's allergy information",
        "PATIENT STATUS": "Allergy Information: No Known Allergies. Adverse Reactions (Nursing Notes): No Hypersensitivity reaction available. Adverse Reactions (DMO / HAE / HAE BCC ADR Note): No Adverse drug reaction available.",
        "DIAGNOSIS SUMMARY": "Diagnosis 1: Diagnosis 1: 1228535013 : CA - Cancer of colon Primary Site 1: Colon",
        "MANAGEMENT FOR THIS VISIT": "Porta cath appt - urgent. inform me appt date See DSO 27/8/25 TCU 26/8/25 Full Blood Count, UE, LFT, CEA OA prebk #1 mMFOLFOX6 28/8/25 KIV adm if unable to get early porta cath Will liase with surg onco regarding fitness to proceed with chemotherapy declined genetic referral chemotherapy info given return advise given ATU: proceed if Haemoglobin > 8 Absolute Neutrophil Count > 1.5 platelet > 100 CCT > 50 Bil < 1.5x ULN, AST/ALT < 2x ULN"
      },
      "subsections": [
        "General",
        "History, Examination and Investigations",
        "Investigations",
        "Clinical and Treatment Summary",
        "PATIENT STATUS",
        "DIAGNOSIS SUMMARY",
        "MANAGEMENT FOR THIS VISIT"
      ],
      "allergies": "NKA"
    }
  ],
  "25-Aug-2025": [
    {
      "doctor": "Chong Qingqing Dawn",
      "section_type": "Pre-clerk Consult",
      "text": {
        "General": "DMO Pre-clerk Consult Note NCC [Charted Location: Pre-Admit] [Authored: 2025-08-25 14:29]- for Visit: H225121881F0004, /ncomplete, Entered, Signed in Full, General CLINICAL NOTES:",
        "History, Examination and Investigations": "Metastatic ascending colon adenoca to lung, liver, LN (OMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction Due #1 mFOLFOX6 30/8/25 came with wife, daughter and sister in law S: Ole: L clear A soft non tender wound healed steristrip over drain side - clean no pedal edema Inv labs ok CEA 538 Hep b neg Imp: fit for chemotherapy explained labs consent to folfox signed spoke to DSO earlier, no contraindications to chemotherapy if wound healed Future Appointments: 27/08/2025 16:00:00 SGH DIETETICS DIT CDLD, BLK 3 B1 (Yellow Zone) 01/09/2025 15:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 30/08/2025 08:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 27/08/2025 14:00:00 NCC SURGERY & SURGICAL ONCOLOGY SON CLINIC 14F -NCCS (Outram) Level 14 Cai Mingzhe 26/08/2025 11:00:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 Chong Qingging Dawn 2025-09-26 14:27  Current Location: NCC ATU L10 26/08/2025 09:00:00 NCC LABORATORY ONC NCCS LABORATORY LAB PERSONNEL - ONCO PATIENTS",
        "Clinical and Treatment Summary": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction pT 3N2b Moderately dydx adenoca #1 mFOLFOX6 30/8/25 PMHx: 1. HTN 2. HLD 3. DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Treatment Intent: Palliative therapy Patient Response: NE ECOG: 1 Pain Score:: 0 Allergy Acknowledgement: | have acknowledged the patient's allergy information",
        "PATIENT STATUS": "Allergy Information: No Known Allergies. Adverse Reactions (Nursing Notes): No Hypersensitivity reaction available.",
        "DIAGNOSIS SUMMARY": "Diagnosis 1: Diagnosis 1: 1228535013 : CA - Cancer of colon Primary Site 1: Colon",
        "MANAGEMENT FOR THIS VISIT": "Porta cath today #1 mFOLFOX6 30/8/25 TCU 11/9/25 Full Blood Count, UE, LFT, CEA OA prebk #2 mFOLFOX6 declined genetic referral return advise given ATU: proceed if Haemoglobin > 8 Absolute Neutrophil Count > 1.5 platelet > 100 CCT > 50 Bil < 1.5x ULN, AST/ALT < 2x ULN 2025-09-26 14:27  ' Current Location: NCC ATU , L10"
      },
      "subsections": [
        "General",
        "History, Examination and Investigations",
        "Clinical and Treatment Summary",
        "PATIENT STATUS",
        "DIAGNOSIS SUMMARY",
        "MANAGEMENT FOR THIS VISIT"
      ],
      "allergies": "NKA"
    }
  ],
  "26-Aug-2025": [
    {
      "doctor": "Chong Qingging Dawn",
      "section_type": "Consult",
      "text": {
        "General": "DMO Consult Note NCC [Charted Location: NCC Clinic 14E] [Authored: 2025-08-26 11:35]- for Visit: H225121881F0004, Complete, Entered, Signed in Full, General Height & Weight: Weight (kg): 64.5 kg 2025-08-26 10:40:54. Height (cm): 171 cm 2025-08-26 10:40:54. CLINICAL NOTES:",
        "History, Examination and Investigations": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction Due #1 mFOLFOX6 30/8/25 came with wife, daughter and sister in law S: BO every 2 days appetite ok no vomting Ole: L clear A soft non tender wound healed steristrip over drain side - clean no pedal edema Inv labs ok no RP CEA 538.447 Hep b neg Imp: fit for chemotherapy pending RP explained labs consent to folfox signed spoke to DSO earlier, no contraindications to chemotherapy if wound healed Future Appointments: 27/08/2025 16:00:00 SGH DIETETICS DIT CDLD, BLK 3 B1 (Yellow Zone) 01/09/2025 15:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 30/08/2025 08:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 27/08/2025 14:00:00 NCC SURGERY & SURGICAL ONCOLOGY SON CLINIC 14F -NCCS (Outram) Level 14 Cai Mingzhe 2025-09-26 14:27  Current Location: NCC ATU L10 26/08/2025 11:00:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 Chong Qingqging Dawn 26/08/2025 09:00:00 NCC LABORATORY ONC NCCS LABORATORY LAB PERSONNEL - ONCO PATIENTS Vital Signs: BP 137 / 75mmHg (12 Aug 2025 16:35:00:000) Ht: 171 cm (2025-08-26 10:40:54) Wt: 64.5 kg (2025-08-26 10:40:54) BSA: 1.75 m2 BMI: 22.1",
        "Clinical and Treatment Summary": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction pT3N2b moderately dydx adenoca #1 mFOLFOX6 30/8/25 PMHx: 1. HTN 2. HLD 3. DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Treatment Intent: Palliative therapy Patient Response: NE ECOG: 1 Pain Score:: 0 Allergy Acknowledgement: | have acknowledged the patient's allergy information",
        "PATIENT STATUS": "Allergy Information: No Known Allergies. Adverse Reactions (Nursing Notes): No Hypersensitivity reaction available. Adverse Reactions (DMO / HAE / HAE BCC ADR Note): No Adverse drug reaction available.",
        "DIAGNOSIS SUMMARY": "Diagnosis 1: Diagnosis 1: 1228535013 : CA - Cancer of colon Primary Site 1: Colon",
        "MANAGEMENT FOR THIS VISIT": "Porta cath today Add RP to today's labs #1 mFOLFOX6 30/8/25 TCU 11/9/25 915 am Full Blood Count, UE, LFT, CEA OA prebk #2 mFOLFOX6 declined genetic referral return advise given ATU: proceed if Haemoglobin > 8 Absolute Neutrophil Count > 1.5 platelet > 100 CCT > 50 Bil < 1.5x ULN, AST/ALT < 2x ULN"
      },
      "subsections": [
        "General",
        "History, Examination and Investigations",
        "Clinical and Treatment Summary",
        "PATIENT STATUS",
        "DIAGNOSIS SUMMARY",
        "MANAGEMENT FOR THIS VISIT"
      ],
      "allergies": "NKA"
    }
  ],
  "10-Sep-2025": [
    {
      "doctor": "Chong Qingging Dawn",
      "section_type": "Pre-clerk Consult",
      "text": {
        "General": "DMO Pre-clerk Consult Note NCC [Charted Location: Pre-Admit] [Authored: 2025-09-10 14:37]- for Visit: H225121881F0007, Incomplete, Entered, Signed in Full, General CLINICAL NOTES:",
        "History, Examination and Investigations": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction Due #2 mFOLFOX6 came with wife, daughter and sister in law S: BO every 2 days appetite ok no vomting Ole: L clear A soft non tender no pedal edema Inv labs ok CEA 538 . 447 Hep B neg 2025-09-26 14:27  Current Location: NCC ATU L10 SSTP Clinically Significant Variants: 1. KRAS (NM 004985.4), Exon4, c.436G>A p. (Alal4o6Thr) [p. (A146T)] AF: 61.80% 2. PIK3CA (NM006218.3), Exon21, c.3140A>G p.(HislO47Arg) [p. (H1047R)] AF: 9.40% 3. PIK3CA (NM006218.3), Exonl0, c.1637A>T p. (Gln546Leu) [p. (Q546L) ] AF: 21.90% 4. APC (NM000038.5), Exonl6, c.4666dupA p.(Thri556fs) [p. (T1556fs)] AF: 25.50% 5. TP53 (NM _000546.5), Exon4, c.319T>G p.(Tyrl107Asp) [p. (Y107D)] AF: 27.10% Variants of Uncertain Clinical Significance (VUS): Nil Imp: fit for chemotherapy explained labs Future Appointments: 15/10/2025 14:30:00 NCC SURGERY & SURGICAL ONCOLOGY SON CLINIC 14F -NCCS (Outram) Level14 Cai Mingzhe 29/09/2025 11:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 27/09/2025 08:30:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 15/09/2025 11:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 13/09/2025 08:30:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 11/09/2025 11:15:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 Chong Qingging Dawn 11/09/2025 09:15:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 DUMMY SOC NURSE,",
        "Clinical and Treatment Summary": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction pI 3N2b moderately dydx adenoca #1 mMFOLFOX6 30/8/25 PMHx: 2025-09-26 14:27  Current Location: NCC ATU L10 1. HTN 2. HLD 3. DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Treatment Intent: Palliative therapy Patient Response: NE ECOG: 1 Pain Score:: 0",
        "PATIENT STATUS": "Allergy Information: No Known Allergies. Adverse Reactions (Nursing Notes): No Hypersensitivity reaction available.",
        "DIAGNOSIS SUMMARY": "Diagnosis 1: Diagnosis 1: 1228535013 : CA - Cancer of colon Primary Site 1: Colon",
        "MANAGEMENT FOR THIS VISIT": "#2 mFOLFOX6 26/9/25 Full Blood Count uecr Liver Function CEA Tests pharm review #3 mMFOLFOX6 TCU 10/10/25 Full Blood Count, UE, LFT, CEA OA prebk #4 mFOLFOX6 declined genetic referral return advise given ATU: proceed if Haemoglobin > 8 Absolute Neutrophil Count > 1.5 platelet > 100 CCT > 50 Bil < 1.5x ULN, AST/ALT < 2x ULN"
      },
      "subsections": [
        "General",
        "History, Examination and Investigations",
        "Clinical and Treatment Summary",
        "PATIENT STATUS",
        "DIAGNOSIS SUMMARY",
        "MANAGEMENT FOR THIS VISIT"
      ],
      "allergies": "NKA"
    }
  ],
  "11-Sep-2025": [
    {
      "doctor": "Chong Qingging Dawn",
      "section_type": "Consult",
      "text": {
        "General": "DMO Consult Note NCC [Charted Location: Pre-Admit] [Authored: 2025-09-11 10:48]- for Visit: H225121881F0007, Complete, Entered, Signed in Full, General Height & Weight: Weight (kg): 63.8 kg 2025-09-11 09:37:15. Height (cm): 171.2 cm 2025-09-11 09:37:15. CLINICAL NOTES:",
        "History, Examination and Investigations": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction Due #2 mFOLFOX6 came with wife, daughter and sister-in-law S: BO every 2 days appetite ok no vomiting no neuropathy Gi fatigue no diarrhea wife says patient has 2 episodes of ?mouth tiliting while on 5FU, called out to patient and immediately can correct no weakness 2025-09-26 14:27  Current Location: NCC ATU L10 Ole: walked in L clear A soft non tender no pedal edema Inv labs ok CEA 538 > 447> pending SSTP Clinically Significant Variants: 1. KRAS (NM_004985.4), Exon4, c.436G>A p.(Ala146Thr) [p.(A146T)] AF: 61.80% 2. PIK3CA (NM_006218.3), Exon21, c.3140A>G p.(His1047Arg) [p.(H1047R)] AF: 9.40% 3. PIK3CA (NM_006218.3), Exon10, c.1637A>T p.(GIn546Leu) [p.(Q546L)] AF: 21.90% 4. APC (NM_000038.5), Exon16, c.4666dupA p.(Thr1556fs) [p.(T 1556fs)] AF: 25.50% 5. TP53 (NM_000546.5), Exon4, c.319T>G p.(Tyr107Asp) [p.(Y107D)] AF: 27.10% Variants of Uncertain Clinical Significance (VUS): Nil Imp: fit for chemotherapy explained labs cont chemotherapy advised to watch for neuro symptoms (?mouth til(weakness/numbness) and to go to EDif it happens again Future Appointments: 15/10/2025 14:30:00 NCC SURGERY & SURGICAL ONCOLOGY SON CLINIC 14F -NCCS (Outram) Level 14 Cai Mingzhe 29/09/2025 11:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 27/09/2025 08:30:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 15/09/2025 11:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 13/09/2025 08:30:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 11/09/2025 11:15:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 Chong Qingqing Dawn 11/09/2025 09:15:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 DUMMY SOC NURSE, Vital Signs: BP 125 / 78mmHg (01 Sep 2025 09:20:00) Ht: 171.2 cm (2025-09-11 09:37:15) Wt: 63.8 kg (2025-09-11 09:37:15) BSA: 1.74 m2 BMI: 21.8 2025-09-26 14:27  Current Location: NCC ATU L10",
        "Clinical and Treatment Summary": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg KRAS (NM_004985.4), Exon4, c.436G>A p.(Ala146Thr) [p.(A146T)]) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction pT3N2b moderately dydx adenoca #1 mFOLFOX6 30/8/25 PMHx: 1. HTN 2. HLD 3. DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Treatment Intent: Palliative therapy Patient Response: NE ECOG: 1 Pain Score:: 0 Allergy Acknowledgement: | have acknowledged the patient's allergy information",
        "PATIENT STATUS": "Allergy Information: No Known Allergies. Adverse Reactions (Nursing Notes): No Hypersensitivity reaction available. Adverse Reactions (DMO / HAE / HAE BCC ADR Note): No Adverse drug reaction available.",
        "DIAGNOSIS SUMMARY": "Diagnosis 1: Diagnosis 1: 1228535013 : CA - Cancer of colon Primary Site 1: Colon",
        "MANAGEMENT FOR THIS VISIT": "#2 mFOLFOX6- increase dose TCU 2 weeks Full Blood Count, UE, LFT, CEA OA prebk #3,4 mFOLFOX6 KIV add bev next cycle declined genetic referral return advise given ATU: proceed if Haemoglobin > 8 Absolute Neutrophil Count > 1.5 platelet > 100 CCT > 50 Bil < 1.5x ULN, AST/ALT < 2x ULN  2025-09-26 14:27  Current Location: NCC ATU L10"
      },
      "subsections": [
        "General",
        "History, Examination and Investigations",
        "Clinical and Treatment Summary",
        "PATIENT STATUS",
        "DIAGNOSIS SUMMARY",
        "MANAGEMENT FOR THIS VISIT"
      ],
      "allergies": "NKA"
    }
  ],
  "22-Sep-2025": [
    {
      "doctor": "Chong Qingging Dawn",
      "section_type": "Pre-clerk Consult",
      "text": {
        "General": "DMO Pre-clerk Consult Note NCC [Charted Location: Pre-Admit] [Authored: 2025-09-22 17:45]- for Visit: H225121881F0010, /ncomplete, Entered, Signed in Full, General CLINICAL NOTES:",
        "History, Examination and Investigations": "Metastatic ascending colon adenoca to lung, liver, LN (ODMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction Due #3 mFOLFOX6 came with wife, daughter and sister-in-law S: BO every 2 days appetite ok no vomiting no neuropathy G1 fatigue no diarrhea wife says patient has 2 episodes of ?mouth tiliting while on 5FU, called out to patient and immediately can correct no weakness Ole: walked in L clear A soft non tender no pedal edema Inv labs ok CEA 538 > 447> 555 SSTP Clinically Significant Variants: 1. KRAS (NM_004985.4), Exon4, c.436G>A p.(Ala146Thr) [p.(A146T)] AF: 61.80% 2. PIK3CA (NM_006218.3), Exon21, c.3140A>G p.(His1047Arg) [p.(H1047R)] AF: 9.40% 3. PIK3CA (NM_006218.3), Exon10, c.1637A>T p.(Gln546Leu) [p.(Q546L)] 2025-09-26 14:27  Current Location: NCC ATU L10 AF: 21.90% 4. APC (NM_000038.5), Exon16, c.4666dupA p.(Thr1556fs) [p.(T1556fs)] AF: 25.50% 5. TP53 (NM_000546.5), Exon4, c.319T>G p.(Tyr107Asp) [p.(107D)] AF: 27.10% Variants of Uncertain Clinical Significance (VUS): Nil Imp: fit for chemotherapy explained labs cont chemotherapy if no evid of stroke, discuss adding on Bev The potential side effects of Bevacizumab have been explained, including but not limited to:Most Common: high blood pressure; An increased risk for blood clots; Dry and/or peeling of skin; Bleeding (usually minor) such as a nosebleed; Allergic reaction and possible fever, chills, or shivering during the infusion; Nausea/Vomiting/taste changes/loss of appetite; Constipation/Diarrhea; Increased risk of infection; Fatigue/tiredness/joint or muscle ache/headache; Pain/discomfort from insertion of needle for drug infusion. Less Common: Altered kidney function (determined by blood test); Abnormal salt blood levels or protein in the urine; Abnormal liver function (determined by blood test that measures liver enzymes) Rare but serious: Changes to the brain that can include: headache- associated with seizure, confusion, tiredness, blindness; Gastrointestinal Perforation (hole in gastrointestinal tract); Stroke; Hemorrhage. When Bevacizumab is given in combination with other drugs including chemotherapy, additional side effects not listed above may occur. These are explained and listed in separate drug-specific information sheets. Patient is aware that in addition to the risks specifically described above, there are other risks that are present with respect to any treatment, and unforeseen conditions may arise which may require that the nature of treatment be altered. Unexpected or unforeseen side effects may also occur. Patient is aware of the goals and anticipated benefits of the proposed treatment and the likelihood of achieving those goals and that there are no guarantees with respect to the results of the proposed treatment. Treatment response is variable. Patient has been given the opportunity to ask any questions regarding his/her condition and given information of alternatives and risks. Patient acknowledges that sufficient information has been given and gives consent to start Bevacizumab. Future Appointments: 15/10/2025 14:30:00 NCC SURGERY& SURGICAL ONCOLOGY SON CLINIC 14F -NCCS (Outram) Level 14 Cai Mingzhe 13/10/2025 10:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 11/10/2025 08:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 29/09/2025 11:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 27/09/2025 08:30:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 25/09/2025 12:00:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 Chong Qingging Dawn 25/09/2025 10:30:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 DUMMY SOC NURSE, 2025-09-26 14:27  Current Location: NCC ATU L10",
        "Clinical and Treatment Summary": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg KRAS (NM_004985.4), Exon4, c.436G>A p.(Ala146Thr) [p.(A146T)]) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction pT3N2b moderately dydx adenoca #1 mFOLFOX6 30/8/25 PMHx: 1. HTN 2. HLD 3. DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Treatment Intent: Palliative therapy Patient Response: NE ECOG: 1 Pain Score:: 0",
        "PATIENT STATUS": "Allergy Information: No Known Allergies. Adverse Reactions (Nursing Notes): No Hypersensitivity reaction available.",
        "DIAGNOSIS SUMMARY": "Diagnosis 1: Diagnosis 1: 1228535013 : CA - Cancer of colon Primary Site 1: Colon",
        "MANAGEMENT FOR THIS VISIT": "#3 mFOLFOX6 kiv add on bev TCU 2 weeks Full Blood Count, UE, LFT, CEA OA prebk #4,5 mFOLFOX6 declined genetic referral return advise given ATU: proceed if Haemoglobin > 8 Absolute Neutrophil Count > 1.5 platelet > 100 CCT > 50 Bil < 1.5x ULN, AST/ALT < 2x ULN  2025-09-26 14:27  Current Location: NCC ATU L10"
      },
      "subsections": [
        "General",
        "History, Examination and Investigations",
        "Clinical and Treatment Summary",
        "PATIENT STATUS",
        "DIAGNOSIS SUMMARY",
        "MANAGEMENT FOR THIS VISIT"
      ],
      "allergies": "NKA"
    }
  ],
  "25-Sep-2025": [
    {
      "doctor": "Chong Qingging Dawn",
      "section_type": "Consult",
      "text": {
        "General": "DMO Consult Note NCC [Charted Location: NCC Clinic 14E] [Authored: 2025-09-25 12:00]- for Visit: H225121881F0010, Complete, Entered, Signed in Full, General Height & Weight: Weight (kg): 63.9 kg 2025-09-25 11:51:37. Height (cm): 170.7 cm 2025-09-25 11:51:37. CLINICAL NOTES:",
        "History, Examination and Investigations": "Metastatic ascending colon adenoca to lung, liver, LN (pMMR, HER2neg SSTP pending) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction Due #3 mFOLFOX6 came with wife, daughter and sister-in-law S: no diarrhea appetite ok no vomiting no neuropathy Gi fatigue taste disturbances half share for meals no more tilting of mouth 2025-09-26 14:27  Current Location: NCC ATU L10 no progesterone receptor bleeding Ole: walked in L clear A soft non tender no pedal edema Inv labs ok CEA 538 > 447> 555 SSTP Clinically Significant Variants: 1. KRAS (NM_004985.4), Exon4, c.436G>A p.(Ala146Thr) [p.(A146T)] AF: 61.80% 2. PIK3CA (NM_006218.3), Exon21, c.3140A>G p.(His1047Arg) [p.(H1047R)] AF: 9.40% 3. PIK3CA (NM_006218.3), Exon10, c.1637A>T p.(GIn546Leu) [p.(Q546L)] AF: 21.90% 4. APC (NM_000038.5), Exon16, c.4666dupA p.(Thr1556fs) [p.(T 1556fs)] AF: 25.50% 5. TP53 (NM_000546.5), Exon4, c.319T>G p.(Tyr107Asp) [p.(Y107D)] AF: 27.10% Variants of Uncertain Clinical Significance (VUS): Nil Imp: fit for chemotherapy explained labs cont chemotherapy The potential side effects of Bevacizumab have been explained, including but not limited to:Most Common: high blood pressure; An increased risk for blood clots; Dry and/or peeling of skin; Bleeding (usually minor) such as a nosebleed; Allergic reaction and possible fever, chills, or shivering during the infusion; Nausea/Vomiting/taste changes/loss of appetite; Constipation/Diarrhea; Increased risk of infection; Fatigue/tiredness/joint or muscle ache/headache; Pain/discomfort from insertion of needle for drug infusion. Less Common: Altered kidney function (determined by blood test); Abnormal salt blood levels or protein in the urine; Abnormal liver function (determined by blood test that measures liver enzymes) Rare but serious: Changes to the brain that can include: headache- associated with seizure, confusion, tiredness, blindness; Gastrointestinal Perforation (hole in gastrointestinal tract); Stroke; Hemorrhage. When Bevacizumab is given in combination with other drugs including chemotherapy, additional side effects not listed above may occur. These are explained and listed in separate drug-specific information sheets. Patient is aware that in addition to the risks specifically described above, there are other risks that are present with respect to any treatment, and unforeseen conditions may arise which may require that the nature of treatment be altered. Unexpected or unforeseen side 2025-09-26 14:27  Current Location: NCC ATU L10 effects may also occur. Patient is aware of the goals and anticipated benefits of the proposed treatment and the likelihood of achieving those goals and that there are no guarantees with respect to the results of the proposed treatment. Treatment response is variable. Patient has been given the opportunity to ask any questions regarding his/her condition and given information of alternatives and risks. patient wants to hold off bev first noted patient recording explained no recording allowed in clinic Future Appointments: 15/10/2025 14:30:00 NCC SURGERY & SURGICAL ONCOLOGY SON CLINIC 14F -NCCS (Outram) Level 14 Cai Mingzhe 13/10/2025 10:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 11/10/2025 08:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 29/09/2025 11:00:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 27/09/2025 08:30:00 NCC MEDICAL ONCOLOGY ONC ATU - New Building Level 10 25/09/2025 12:00:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 Chong Qingqging Dawn 25/09/2025 10:30:00 NCC MEDICAL ONCOLOGY ONC CLINIC 14E -NCCS (Outram) Level 14 DUMMY SOC NURSE, Vital Signs: BP 129 / 81mmHg (15 Sep 2025 11:20:00) Ht: 170.7 cm (2025-09-25 11:51:37) Wt: 63.9 kg (2025-09-25 11:51:37) BSA: 1.74 m2 BMI: 21.9",
        "Clinical and Treatment Summary": "Metastatic ascending colon adenoca to lung, liver, LN (OMMR, HER2neg KRAS (NM_004985.4), Exon4, c.436G>A p.(Ala146Thr) [p.(A146T)]) Diagnostic laparoscopy and limited right hemicolectomy on 7/8/25 for impending obstruction pI 3N2b moderately dydx adenoca #1 mMFOLFOX6 30/8/25 PMHx: 1. HTN 2. HLD 3. DM - HbA1c 7.1% 31/7/25 - with possible nephropathy UACR 7mg/mmol Treatment Intent: Palliative therapy Patient Response: NE ECOG: 1 Pain Score:: 0 Allergy Acknowledgement: | have acknowledged the patient's allergy information",
        "PATIENT STATUS": "Allergy Information: 2025-09-26 14:27  Current Location: NCC ATU L10 No Known Allergies. Adverse Reactions (Nursing Notes): No Hypersensitivity reaction available. Adverse Reactions (DMO / HAE / HAE BCC ADR Note): No Adverse drug reaction available.",
        "DIAGNOSIS SUMMARY": "Diagnosis 1: Diagnosis 1: 1228535013 : CA - Cancer of colon Primary Site 1: Colon",
        "MANAGEMENT FOR THIS VISIT": "#3 mFOLFOX6 TCU 2 weeks Full Blood Count, UE, LFT, CEA OA prebk #4,5 mFOLFOX6 declined genetic referral return advise given ATU: proceed if Haemoglobin > 8 Absolute Neutrophil Count > 1.5 platelet > 100 CCT > 50 Bil < 1.5x ULN, AST/ALT < 2x ULN"
      },
      "subsections": [
        "General",
        "History, Examination and Investigations",
        "Clinical and Treatment Summary",
        "PATIENT STATUS",
        "DIAGNOSIS SUMMARY",
        "MANAGEMENT FOR THIS VISIT"
      ],
      "allergies": "NKA"
    }
  ]
}